210 related articles for article (PubMed ID: 25666683)
1. Current approaches for in vitro drug release study of long acting parenteral formulations.
Dadhaniya TM; Sharma OP; Gohel MC; Mehta PJ
Curr Drug Deliv; 2015; 12(3):256-70. PubMed ID: 25666683
[TBL] [Abstract][Full Text] [Related]
2. An overview of in vitro dissolution/release methods for novel mucosal drug delivery systems.
Jug M; Hafner A; Lovrić J; Kregar ML; Pepić I; Vanić Ž; Cetina-Čižmek B; Filipović-Grčić J
J Pharm Biomed Anal; 2018 Jan; 147():350-366. PubMed ID: 28720350
[TBL] [Abstract][Full Text] [Related]
3. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
Schilderink R; Protopappa M; Fleth-James J; Vertzoni M; Schaefer K; Havenaar R; Kulla I; Metzger M; Reppas C
Eur J Pharm Biopharm; 2020 Apr; 149():154-162. PubMed ID: 32057905
[TBL] [Abstract][Full Text] [Related]
4. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
Seidlitz A; Weitschies W
J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343
[TBL] [Abstract][Full Text] [Related]
5. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
Somayaji MR; Das D; Przekwas A
Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
[TBL] [Abstract][Full Text] [Related]
6. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review.
Ditzinger F; Price DJ; Ilie AR; Köhl NJ; Jankovic S; Tsakiridou G; Aleandri S; Kalantzi L; Holm R; Nair A; Saal C; Griffin B; Kuentz M
J Pharm Pharmacol; 2019 Apr; 71(4):464-482. PubMed ID: 30070363
[TBL] [Abstract][Full Text] [Related]
7. Interpreting
Rudd ND; Reibarkh M; Fang R; Mittal S; Walsh PL; Brunskill APJ; Forrest WP
Mol Pharm; 2020 May; 17(5):1734-1747. PubMed ID: 32267708
[TBL] [Abstract][Full Text] [Related]
8. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
[TBL] [Abstract][Full Text] [Related]
9. Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs.
Radivojev S; Zellnitz S; Paudel A; Fröhlich E
Int J Pharm; 2019 Feb; 556():45-56. PubMed ID: 30529665
[TBL] [Abstract][Full Text] [Related]
10. Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.
Bauer A; Berben P; Chakravarthi SS; Chattorraj S; Garg A; Gourdon B; Heimbach T; Huang Y; Morrison C; Mundhra D; Palaparthy R; Saha P; Siemons M; Shaik NA; Shi Y; Shum S; Thakral NK; Urva S; Vargo R; Koganti VR; Barrett SE
Pharm Res; 2023 Jul; 40(7):1601-1631. PubMed ID: 36811809
[TBL] [Abstract][Full Text] [Related]
11. USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.
Forrest WP; Reuter KG; Shah V; Kazakevich I; Heslinga M; Dudhat S; Patel S; Neri C; Mao Y
AAPS PharmSciTech; 2018 Jan; 19(1):413-424. PubMed ID: 28755052
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of accelerated drug release testing methods for a matrix-type intravaginal ring.
Externbrink A; Eggenreich K; Eder S; Mohr S; Nickisch K; Klein S
Eur J Pharm Biopharm; 2017 Jan; 110():1-12. PubMed ID: 27793758
[TBL] [Abstract][Full Text] [Related]
14. A biorelevant dissolution stress test device - background and experiences.
Garbacz G; Klein S; Weitschies W
Expert Opin Drug Deliv; 2010 Nov; 7(11):1251-61. PubMed ID: 20977290
[TBL] [Abstract][Full Text] [Related]
15. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
Ali J; Zgair A; Hameed GS; Garnett MC; Roberts CJ; Burley JC; Gershkovich P
Int J Pharm; 2019 Jan; 555():228-236. PubMed ID: 30465852
[TBL] [Abstract][Full Text] [Related]
16. Scientific and regulatory standards for assessing product performance using the similarity factor, f2.
Stevens RE; Gray V; Dorantes A; Gold L; Pham L
AAPS J; 2015 Mar; 17(2):301-6. PubMed ID: 25669756
[TBL] [Abstract][Full Text] [Related]
17. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems.
Phillips DJ; Pygall SR; Cooper VB; Mann JC
J Pharm Pharmacol; 2012 Nov; 64(11):1549-59. PubMed ID: 23058042
[TBL] [Abstract][Full Text] [Related]
18. Role of in vitro release models in formulation development and quality control of parenteral depots.
Larsen C; Larsen SW; Jensen H; Yaghmur A; Ostergaard J
Expert Opin Drug Deliv; 2009 Dec; 6(12):1283-95. PubMed ID: 19941410
[TBL] [Abstract][Full Text] [Related]
19. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
20. Dissolution Profiles of Immediate Release Products of Various Drugs in Biorelevant Bicarbonate Buffer: Comparison with Compendial Phosphate Buffer.
Okamoto N; Higashino M; Yamamoto H; Sugano K
Pharm Res; 2024 May; 41(5):959-966. PubMed ID: 38653942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
